Practical Methods Using Boronic Acid Compounds for Identification of Class C β-Lactamase-ProducingKlebsiella pneumoniaeandEscherichia coli
Open Access
- 1 June 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 43 (6) , 2551-2558
- https://doi.org/10.1128/jcm.43.6.2551-2558.2005
Abstract
Detection of the resistance mediated by class C β-lactamases remains a challenging issue, considering that transferable plasmid-mediated class C β-lactamases are of worldwide concern. Methods for the identification of strains that produce extended-spectrum β-lactamases (ESBLs) or metallo-β-lactamases (MBLs) have been developed and applied for routine use in clinical microbiology laboratories, but no practical methods for identification of plasmid-mediated class C producers have been established to date. We therefore developed three simple methods for clinical microbiology laboratories that allow identification of plasmid-mediated class C β-lactamase-producing bacteria using a boronic acid derivative, 3-aminophenylboronic acid (APB), one of the specific inhibitors of class C β-lactamases. Detection by the disk potentiation test was based on the enlargement of the growth-inhibitory zone diameter (by greater than or equal to 5 mm) around a Kirby-Bauer disk containing a ceftazidime (CAZ) or a cefotaxime (CTX) disk in combination with APB. In a double-disk synergy test, the discernible expansion of the growth-inhibitory zone around the CAZ or the CTX disk toward a disk containing APB was indicative of class C β-lactamase production. A greater than or equal to eightfold decrease in the MIC of CAZ or CTX in the presence of APB was the criterion for detection in the microdilution test. By using these methods, Escherichia coli and Klebsiella pneumoniae isolates producing plasmid-mediated class C β-lactamases, ACT-1, CMY-2, CMY-9, FOX-5, LAT-1, and MOX-1, were successfully distinguished from those producing other classes of β-lactamases, such as ESBLs and MBLs. These methods will provide useful information needed for targeted antimicrobial therapy and better infection control.Keywords
This publication has 47 references indexed in Scilit:
- Molecular Characterization of a Cephamycin-Hydrolyzing and Inhibitor-Resistant Class A β-Lactamase, GES-4, Possessing a Single G170S Substitution in the Ω-LoopAntimicrobial Agents and Chemotherapy, 2004
- Inhibitor-Sensitive AmpC β-Lactamase Variant Produced by an Escherichia coli Clinical Isolate Resistant to Oxyiminocephalosporins and CephamycinsAntimicrobial Agents and Chemotherapy, 2004
- A New TEM-Derived Extended-Spectrum β-Lactamase (TEM-91) with an R164C Substitution at the Ω-Loop Confers Ceftazidime ResistanceAntimicrobial Agents and Chemotherapy, 2003
- Further modification of the Hodge test to screen AmpC β-lactamase (CMY-1)-producing strains of Escherichia coli and Klebsiella pneumoniaeJournal of Microbiological Methods, 2002
- Characterization of a Novel Plasmid-Mediated Cephalosporinase (CMY-9) and Its Genetic Environment in anEscherichia coliClinical IsolateAntimicrobial Agents and Chemotherapy, 2002
- Development of a Sensitive and Specific Enzyme-Linked Immunosorbent Assay for Detecting and Quantifying CMY-2 and SHV β-LactamasesJournal of Clinical Microbiology, 2002
- A New SHV-Derived Extended-Spectrum β-Lactamase (SHV-24) That Hydrolyzes Ceftazidime through a Single-Amino-Acid Substitution (D179G) in the Ω-LoopAntimicrobial Agents and Chemotherapy, 2000
- Outbreak ofKlebsiella pneumoniaeproducing transferable AmpC-type β-lactamase (ACC-1) originating fromHafnia alveiFEMS Microbiology Letters, 2000
- Ceftriaxone-Resistant Salmonella Infection Acquired by a Child from CattleNew England Journal of Medicine, 2000
- A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates ofKlebsiella pneumoniaeandEscherichia coliin JapanFEMS Microbiology Letters, 2000